China’s Innovative Drug Sector is Exploding: Here’s Why Investors Are BuzzingChina Finance Tech in China3SBio, Biotechnology, Bohai Securities, Changshan Pharma, China Securities, Cinda Securities, CSPC Pharmaceutical Group, Everbright Securities, Haichen Pharmaceutical, Healthcare, Huafu Securities, Innovative Drugs, Joincare Pharmaceutical, Lianhe Chemical Technology, Luoxin Pharmaceutical, Medicilon, NMPA, Pfizer, Pharmaceuticals, Shenyang Sansheng, Sunshine Guojian, Xiangcai Securities June 9, 2025
STAR Market Pharma 2024 Report Card: Profit Growth for 53%, R&D Spend Hits ¥350M AverageChina Finance Tech in ChinaBeiGene, Biopharma, BioRay Pharmaceutical, EndoPuls Therapeutics, Jiangsu Jindiaok Biotechnology, Junshi Biosciences, Kexing Biopharm, Medicilon, MicroPort EP, Nansin Pharm, Notta & Belle, Profitability, R&D, RemeGen, SinoCellTech, STAR Market, Sunny Pharmatech, Sunshine Guojian Pharmaceutical, Tinavi Medical Technologies, United Imaging Healthcare, Xiangyu Medical, Zhixiang Bio May 6, 2025
